Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Problems in ML II and III: Extra-skeletal Manifestations

  • Park, Sung Won (Department of Pediatrics, Cheil General Hospital and Woman's Health Care Center, Dankook University College of Medicine)
  • Received : 2016.06.12
  • Accepted : 2016.06.20
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Mucolipidoses II and III alpha/beta (ML II and ML III) are lysosomal disorders in which the essential mannose-6-phosphate recognition marker is not synthesized onto lysosomal hydrolases and other glycoproteins. The disorders are caused by mutations in GNPTAB, which encodes two of three subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase ML II, recognizable at birth, often causes intrauterine growth impairment and sometimes the prenatal "Pacman" dysplasia. The main postnatal manifestations of ML II include gradual coarsening of neonatally evident craniofacial features, early cessation of statural growth and neuromotor development, dysostosis multiplex and major morbidity by hardening of soft connective tissue about the joints and in the cardiac valves. Fatal outcome occurs often before or in early childhood. ML III with clinical onset rarely detectable before three years of age, progresses slowly with gradual coarsening of the facial features, growth deficiency, dysostosis multiplex, restriction of movement in all joints before or from adolescence, painful gait impairment by prominent hip disease. Cognitive handicap remains minor or absent even in the adult, often wheelchair-bound patient with variable though significantly reduced life expectancy. As yet, there is no cure for individuals affected by these diseases. So, clinical manifestations and conservative treatment is important. This review aimed to highlight the extra-skeletal clinical problems in ML II and III.

Keywords

References

  1. Meikle PJ HJ, Clague AE, Carey WF. Prevalence of Lysosomal Storage Disorders. JAMA 1999;281:249-54. https://doi.org/10.1001/jama.281.3.249
  2. Kornfeld SS, W. I-Cell Disease and Pseudo-Hurler Polydystrophy: Disorders of Lysosomal Enzyme Phosphorylation and Localization. In: Scriver CR, Beaudet AL, Sly, WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. 8. New York: McGraw-Hill;2001:3469-82.
  3. Sly WS, V. In: Lloyd KK, Scriver CR, editors. The I-Cell model: the molecular basis for abnormal lysosomal enzyme transport in mucolipidosis II and mucolipidosis III. Genetic and Metabolic Disease in Pediatrics 1985; London: 91-110.
  4. Leroy J DR. I-Cell Disease. Birth Defects: Original Article Series. Opitz J 1969;5:174-87.
  5. Okada S OM, Sakiyama T, Yutaka T, Ogawa M. I-cell disease: clinical studies of 21 Japanese cases. Clin Genet 1985;28:207-15.
  6. Maroteaux P LM. ML III is a milder disorder with attenuated characteristics and survival to adult life. La pseudopolydystrophie de Hurler. Presse Med 1966;1966:2889-95.
  7. Kelly TE TG, Taylor HA Jr, McKusick VA, Sly WS, Glaser JH, Robinow M, Luzzatti L,Espiritu C, Feingold M, Bull MJ, Ashenhurst EM, Ives EJ. Johns Mucolipidosis III (pseudo- Hurler polydystrophy): Clinical and laboratory studies in a series of 12 patients. Hopkins Med J 1975;137:156-75.
  8. MUCOPOLYSACCHARIDOSES AND MUCOLIPIDOSES. Handbook of Clinical Neurology,;113:Pediatric Neurology Part III Chapter 177.
  9. Sara S. Cathey JGL, Tim Wood, Karisa Eaves, Richard J. Simensen, Mariko Kudo, Roger E. Stevenson, and Michael J. Friez. Phenotype and Genotype in Mucolipidoses II and III alpha/beta: A Study of 61 Probands. J Med Genet 2010;47:38-48. https://doi.org/10.1136/jmg.2009.067736
  10. Hoof FV. Mucopolysaccharidoses and mucolipidoses. J. clin. Path;27, Suppl.:64-93.
  11. Lee W ODD. Severe gingival hyperplasia in a child with Icell disease. Int J Paediatr Dent 2003;13:41-5. https://doi.org/10.1046/j.1365-263X.2003.00419.x
  12. Melo MD OG. Radiolucent lesions of the maxillofacial complex in a patient with mucolipidosis type II (MLSII): case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007:30-3.
  13. Nishimura F NH, Naruishi K, Yamada T, Sasaki J, Peters C, et al. Cathepsin-L, a key molecule in the pathogenesis of drug-induced and I-cell disease-mediated gingival overgrowth. Am J Pathol 2002;161:2047-52. https://doi.org/10.1016/S0002-9440(10)64483-5
  14. Cathey SS lJ, Wood T, Eaves K, Si. mensen rJ, Kudo M, Stevenson rE, et al. Phenotype and genotype in mucolipidoses ii and iii alpha/beta: a study of 61 probands. Journal of medical genetics 2010;47:38-48. https://doi.org/10.1136/jmg.2009.067736
  15. Leroy JG MJ. Mucolipidosis ii (i-cell dis.ease): present status of knowledge. birth defects original article series 1975;11:283-93.
  16. Paik KH SS, Ki CS, Yu HW, Kim JS, Min KH, Chang SH, et al. identification of mutations in the GnPTA (MGC4170) gene coding for GlcnAc-phosphotransferase alpha/beta subunits in Korean patients with mucolipidosis type ii or type iiiA. Human mutation 2005;26:308-14. https://doi.org/10.1002/humu.20205